Both Pro and RS-Pro attenuated cachexia symptoms induced by colon carcinoma and 5-FU chemotherapy by modulating tumor-derived proinflammatory cytokines and regulating the NF-κB pathway within the tumor tissue. Here, NFKB1 is linked to colon carcinoma.